ABSTRACT
Background@#Patients with skin barrier dysfunction often coincides with pruritus, creating a ‘vicious cycle’ of dry skin and itching. Recently, Cynanchum atratum (CA) extract and its constituents have demonstrated effects on atopic dermatitis both in vivo and in vitro. @*Objective@#This study aimed to assess the safety and efficacy of a moisturizer infused with CA extract in enhancing epidermal barrier function and reducing pruritus. @*Methods@#A total 36 participants with skin barrier dysfunction with pruritus (mean age: 46.22±12.48 years) applied the CA-containing moisturizer topically twice daily for up to 4 weeks. Treatment efficacy was assessed by the investigator using the erythema scaling induration fissuring (ESIF) scale, transepidermal water loss (TEWL), skin hydration, visual analogue scale (VAS) for pruritus, and overall patient satisfaction assessed via questionnaire. @*Results@#The CA-containing moisturizer demonstrated favorable tolerability, and yielded significant pruritus relief as evidenced by VAS scores after 2 and 4 weeks of application (p＜0.05). Significant decreases in TEWL (p＜0.05) and skin hydration (p＜0.05) were observed after 2 and 4 weeks, indicating enhanced skin barrier function. Moreover, significant relief from pruritus and reductions in ESIF were observed at 2 and 4 weeks of application (p ＜0.05), aligning with the high levels of patient satisfaction was high. @*Conclusion@#The CA-infused moisturizer emerged as a safe and effective intervention for restoring skin barrier function and providing itch relief.
ABSTRACT
BACKGROUND: The symptoms of atopic dermatitis (AD) may lead to the impairment of overall quality of life (QOL). Many international studies have addressed the effects of AD on the QOL of patients and their families'. However, studies from Korea are few and insufficient. OBJECTIVE: The purpose of this study was to identify the correlation between the QOL and clinical disease severity in adults with AD. METHODS: Thirty-one AD patients ranging in age from 19~43 years were included. Dermatology Life Quality Index (DLQI) and the shorter version of World Health Organization QOL assessment instrument (WHOQOL-BREF) were used to determine the QOL. Eczema area and severity index (EASI) was examined to evaluate the severity of AD. RESULTS: The mean DLQI, QOL and EASI score was 19.74+/-6.93, 3.77+/-0.76 and 9.42+/-11.12, respectively. DLQI and QOL scores significantly correlated with EASI score (p0.05). Each domain of the WHOQOL-BREF and EASI score did not show meaningful correlation (p>0.05). However, for DLQI, categories of emotion, daily life, work and school work showed a high correlation with the EASI score (all p<0.05). Both DLQI and QOL score showed significant correlation with the EASI score in females (p<0.05), but only QOL score showed high correlation in male (p<0.05). CONCLUSION: AD affects QOL of adults with AD as the disease severity increases. In managing the AD patients, evaluating the clinical severity and evaluating QOL of patients would be necessary and emotional support will be helpful.
Subject(s)
Adult , Female , Humans , Male , Dermatitis, Atopic , Dermatology , Eczema , Korea , Quality of Life , World Health OrganizationABSTRACT
The use of ophthalmic drugs and contact lens solutions has increased and allergic contact dermatitis due to these agents has also recently increased. The first case was a 67-year-old female patient who developed allergic contact dermatitis after application of Latano(R): The patch test with the ingredients in Latano(R) showed positive reaction to latanoprost and benzalkonium chloride. The second case was a 63-year-old female patient who developed allergic contact dermatitis after application of Ecolicin(R), Tolon(R), Forus(R) and Uniten-F(R): The patch test showed a positive reaction to Tolon(R). She didn't want further evaluation. The third case was a 51-year-old female patient who developed allergic contact dermatitis after application of Terramycin(R) eye ointment: the patch test with the ingredients of Terramycin(R) eye ointment showed a positive reaction to polymyxin B. When contact dermatitis occurs in periorbital areas, topical ophthalmic ointment or lens cleanser needs to be considered as a causative agent.